Fisher & Paykel Healthcare — Shareholder Meeting (2011)

6 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2011

Slide 1: Consistent Growth Strategy
Consistent Growth Strategy US $ Millions Operating Revenue 371.0 • Innovative devices which 341.5 299.3 improve care and outcomes 271.5 229.1 • Increase value per patient • New applications • International expansion 07 08 09 10 11 2
Slide 2: Financial Summary
Financial Summary • Operating revenue NZ$506.1M +1% US$371.0M +9% • Net profit* NZ$63.9M -11% • Operating margin 19% • Consumable and accessory products 76% of core product revenue Operating revenue * Prior to deferred tax charge 12 months to 31 March 2011 3 Expanding Sales Operations New direct sal
Slide 3: Respiratory & Acute Care
Respiratory & Acute Care 5 New Applications 6
Slide 4: Obstructive Sleep Apnea ICON Flow Generator Range
Obstructive Sleep Apnea 7 ICON Flow Generator Range Novo Auto Premo 8
Slide 5: Research & Development
Research & Development • NZ$39M R&D investment +11% • New products – Evaqua II breathing circuits – Infant CPAP masks – Infant resucitator consumbles – Humigard surgical humidification – Airvo humidity therapy in USA – Masks, OSA and NIV – InfoGSM wireless data system 9 Outlook - Drivers • Reduced e
Slide 6: Outlook
Outlook First Half • Operating revenue – NZ$250 million approx. • Profit after tax – NZ$27 million approx. Full Year • Expect over NZD:USD exchange rate range of 0.85 - 0.80 – Operating revenue NZ$515M - NZ$530M – Net profit after tax NZ$60M - NZ$65M 11